Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.87)
# 1,867
Out of 4,414 analysts
15
Total ratings
38.46%
Success rate
-6.51%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Initiates: Outperform | $65 | $23.98 | +171.06% | 1 | Apr 3, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: In-Line | $108 → $138 | $130.63 | +5.64% | 6 | Feb 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $594 → $436 | $393.42 | +10.82% | 2 | Dec 21, 2023 | |
| MIRM Mirum Pharmaceuticals | Reinstates: Outperform | $62 | $25.60 | +142.19% | 1 | Oct 17, 2023 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $1.31 | +1,579.39% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $6.43 | +55.52% | 1 | May 30, 2023 | |
| ABBV AbbVie | Maintains: Outperform | $159 → $165 | $160.81 | +2.61% | 2 | Feb 9, 2023 | |
| INBX Inhibrx | Maintains: Outperform | $54 → $60 | $34.01 | +76.42% | 1 | Oct 5, 2022 |
Jasper Therapeutics
Apr 3, 2024
Initiates: Outperform
Price Target: $65
Current: $23.98
Upside: +171.06%
Sarepta Therapeutics
Feb 20, 2024
Maintains: In-Line
Price Target: $108 → $138
Current: $130.63
Upside: +5.64%
argenx SE
Dec 21, 2023
Maintains: Outperform
Price Target: $594 → $436
Current: $393.42
Upside: +10.82%
Mirum Pharmaceuticals
Oct 17, 2023
Reinstates: Outperform
Price Target: $62
Current: $25.60
Upside: +142.19%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.31
Upside: +1,579.39%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $6.43
Upside: +55.52%
AbbVie
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $160.81
Upside: +2.61%
Inhibrx
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $34.01
Upside: +76.42%